Get the Stockscreener App
1.60
1.23%
-0.02
After Hours:
1.60
Neuraxis Inc stock is traded at $1.60, with a volume of 2,093.
It is down -1.23% in the last 24 hours and down -24.88% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$1.62
Open:
$1.61
24h Volume:
2,093
Relative Volume:
0.08
Market Cap:
$12.48M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-1.9836
EPS:
-0.8066
Net Cash Flow:
-
1W Performance:
-10.61%
1M Performance:
-24.88%
6M Performance:
-45.76%
1Y Performance:
-48.39%
1-Day Range:
$1.55
$1.71
1-Week Range:
$1.33
$2.00
52-Week Range:
$1.33
$3.78
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
1.60 | 12.48M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Neuraxis Inc Stock (NRXS) Latest News
NRXS stock touches 52-week low at $1.38 amid market challenges By Investing.com - Investing.com South Africa
NRXS stock touches 52-week low at $1.38 amid market challenges - Investing.com India
NeurAxis to Present at the Planet MicroCap Showcase: VEGAS - GlobeNewswire
NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on - Bluefield Daily Telegraph
NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025 - The Globe and Mail
Vagus Nerve Stimulators Market Deep Research Report with - openPR.com
Critical Analysis: CeriBell (NASDAQ:CBLL) versus NeurAxis (NASDAQ:NRXS) - Defense World
Neuraxis stock hits 52-week low at $1.98 amid market challenges By Investing.com - Investing.com South Africa
Neuraxis stock hits 52-week low at $1.98 amid market challenges - Investing.com India
NeurAxis, Inc. (NASDAQ:NRXS) Q4 2024 Earnings Call Transcript - MSN
NeurAxis (NASDAQ:NRXS) Trading Down 0.9% – Should You Sell? - Defense World
NeurAxis Stock Gains Post Q4 Earnings And Revenue Growth - Barchart
NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth - Zacks Investment Research
NeurAxis (NASDAQ:NRXS) & BioLife Solutions (NASDAQ:BLFS) Head-To-Head Analysis - Defense World
NeurAxis, Inc. Reports Strong Q4 Growth Amid Challenges - TipRanks
NeurAxis revenues increase 43% to USD 761K in Q4 2024 - Medical Buyer
NeurAxis, Inc. Reports Strong Q4 2024 Results - TipRanks
Earnings call transcript: Neuraxis Q4 2024 sees revenue growth, loss narrows - Investing.com Canada
Earnings call transcript: Neuraxis Q4 2024 sees revenue growth, loss narrows By Investing.com - Investing.com South Africa
NeurAxis Better on Q4 Results - Baystreet.ca
NeurAxis, Inc. Reports 43% Revenue Growth in Q4 2024 and Significant Milestones Achieved - Nasdaq
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues - GlobeNewswire
Earnings Scheduled For March 20, 2025 - Benzinga
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025 - The Manila Times
NeurAxis, Inc. Set to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 20, 2025 - Nasdaq
NRXS stock touches 52-week low at $1.99 amid market challenges By Investing.com - Investing.com South Africa
NRXS stock touches 52-week low at $1.99 amid market challenges - Investing.com
Vagus Nerve Stimulators Market Detailed In New Research Report - openPR
NeurAxis (NASDAQ:NRXS) Stock Price Down 2.8% – Here’s Why - Defense World
Chronic Idiopathic Constipation Clinical Trials and Pipeline - openPR
Critical Contrast: NeurAxis (NASDAQ:NRXS) & Zynex (NASDAQ:ZYXI) - Defense World
Vagus Nerve Stimulators Market Witness Growth: Booming Demand, - openPR
Analyzing NeurAxis (NASDAQ:NRXS) and Masimo (NASDAQ:MASI) - Defense World
End Of January 2025 Portfolio Review - substack.com
FDA Clears NeurAxis’ Self-Inflating Balloon Device - MPO-mag
Financial Contrast: NeurAxis (NASDAQ:NRXS) versus ENDRA Life Sciences (NASDAQ:NDRA) - Defense World
NeurAxis, Inc. Announces New Medical Policy Coverage with a Prominent Insurer for over Five Million Lives Across Multiple States - Marketscreener.com
UPDATENeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States - The Manila Times
NeurAxis Expands IBS Treatment Coverage to 51M Lives, Targets Youth Market with Novel Device - StockTitan
NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States - The Manila Times
NeurAxis Announces New Medical Policy Coverage with Molina - GlobeNewswire
NeurAxis Expands Coverage for FDA-Cleared IBS Pain Device to 51M Lives with Molina Deal - StockTitan
NeurAxis announces Q4 preliminary unaudited revenues were about $800 thousand - MSN
Vagus Nerve Stimulators Market Growth in Future Scope 2025-2032 - openPR
Critical Analysis: Precision Optics (NASDAQ:POCI) & NeurAxis (NASDAQ:NRXS) - Defense World
Neuraxis Inc Stock (NRXS) Financials Data
There is no financial data for Neuraxis Inc (NRXS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.51%
Cap:
|
Volume (24h):